Trials with limitations
The below list represents drug candidates in Phase 2 clinical trails that our Symphony™ platform provides rationale for efficacy, however, our scientists and researchers have questions or concerns as noted below.
See our list of candidates we predict will achieve efficacy in Phase 2 trials.
DISEASE | DRUG | MECHANISM OF ACTION | NOVEL MECHANISM OF ACTION IN DISEASE | CLINICAL TRIAL END DATE | CLINICAL TRIAL LINK | PREDICTION PUBLISHED DATE | REASON FOR CONCERN |
---|---|---|---|---|---|---|---|
Systemic Sclerosis (SSc) | SHP-627 | TGFB1 & PDGF Inhibitor | No | November 2022 | August 31, 2022 | Too few patients in the clinical trial (30); also concerns about the potency and selectivity of the reported mechanism of action | |
Ankylosing Spondylitis | Jaktinib | JAK inhibitor | No | December 2022 | August 31, 2022 | Tolerability given Jaktinib's broad JAK inhibition | |
Atopic Dermatitis | Jaktinib | JAK inhibitor- | No | December 2022 | August 31, 2022 | Tolerability given Jaktinib's broad JAK inhibition | |
Lupus Nephritis | Pegcetacoplan | C3 inhibitor | Yes | December 2022 | August 31, 2022 | Too few patients in the clinical trial (21) |
Aria’s drug discovery engine.
Drug discovery is complex. Our technology decodes complex biology in an unprecedented manner, combining the widest biomedical data landscapes available with proprietary, purpose-built artificial intelligence. Symphony™ is the only AI drug discovery platform that integrates and simultaneously analyzes unrelated heterogenous data in one process. We see the whole picture, increasing our chance of fully understanding the biology and detecting a signal others can’t see.